OncoMatch/Clinical Trials/NCT07631338
Low-grade Gliomas in Argentina: Incidence, Survival, and Therapeutic Strategies
Is NCT07631338 recruiting? Yes, currently enrolling (Jul 2026).
Low-grade gliomas (LGG) are slow-growing primary brain tumors (WHO grades I-II), and their incidence, survival, and treatment patterns in middle-income settings such as Argentina remain poorly characterized. This retrospective, multicenter study comprises two complementary cohorts: 1. Cohort 1: The "captive" population covered under the Hospital Italiano de Buenos Aires Health Plan (January 2011-December 2023) to estimate LGG incidence density. 2. Cohort 2: Histologically confirmed LGG patients treated at the major referral centers to describe overall survival (OS) and disease-free survival (DFS) at 1 and 5 years. Demographic, clinical, pathological, and treatment data will be collected in a centralized REDCap database. The primary objective is to describe LGG incidence in Argentina and estimate survival using Kaplan-Meier curves. The secondary objectives include characterizing therapeutic strategies, molecular mutations, and prognostic factors through Cox regression analysis. This registry will fill a critical gap in LGG epidemiology in middle-income countries and generate hypotheses for future research.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage WHO GRADE I, WHO GRADE II (other)
WHO grades I and II
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07631338 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage WHO GRADE I or WHO GRADE II is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages